Cempra (CEMP) Receives Daily News Impact Rating of 0.12

Media headlines about Cempra (NASDAQ:CEMP) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cempra earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.9202398983139 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several research analysts have recently commented on the company. Stifel Nicolaus reaffirmed a “hold” rating and issued a $4.00 price objective on shares of Cempra in a research note on Thursday, August 10th. Roth Capital downgraded Cempra from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $8.00 to $4.00 in a research note on Thursday, August 10th. Zacks Investment Research raised Cempra from a “hold” rating to a “buy” rating and set a $3.50 price objective on the stock in a research note on Friday, August 11th. Finally, Jefferies Group LLC reaffirmed a “neutral” rating on shares of Cempra in a research note on Thursday, October 26th. Four investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $8.50.

Cempra (NASDAQ CEMP) traded up 3.37% during mid-day trading on Tuesday, hitting $2.30. The company had a trading volume of 1,282,480 shares. The firm’s market capitalization is $120.77 million. Cempra has a 12 month low of $2.05 and a 12 month high of $18.90. The company has a 50-day moving average price of $3.01 and a 200 day moving average price of $3.61.

Cempra (NASDAQ:CEMP) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. The company had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $3.58 million. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. Cempra’s quarterly revenue was down 74.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.51) EPS. Equities analysts forecast that Cempra will post ($1.02) EPS for the current fiscal year.

WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/10/31/cempra-cemp-receives-daily-news-impact-rating-of-0-12.html.

About Cempra

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Insider Buying and Selling by Quarter for Cempra (NASDAQ:CEMP)

What are top analysts saying about Cempra Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cempra Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit